33.49
price up icon3.36%   1.09
pre-market  Pre-market:  33.94   0.45   +1.34%
loading
Beam Therapeutics Inc stock is traded at $33.49, with a volume of 2.01M. It is up +3.36% in the last 24 hours and up +42.88% over the past month. Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$32.40
Open:
$33.76
24h Volume:
2.01M
Relative Volume:
1.74
Market Cap:
$2.77B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-18.50
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+24.73%
1M Performance:
+42.88%
6M Performance:
+37.09%
1Y Performance:
+1.79%
1-Day Range:
Value
$33.07
$35.25
1-Week Range:
Value
$26.23
$35.25
52-Week Range:
Value
$20.84
$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
374
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
33.49 2.77B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.11 118.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.00 74.34B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
639.00 38.83B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.00 32.36B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.75 29.43B 3.30B -501.07M 1.03B -2.1146

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-29-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-06-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Jul-23-24 Initiated H.C. Wainwright Buy
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
Feb 18, 2025

Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 17.9%Here's What Happened - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Beam Therapeutics (BEAM) to Release Earnings on Tuesday - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Baillie Gifford & Co. Decreases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Next Generation Genome Editing Market Top Companies Study - openPR

Feb 18, 2025
pulisher
Feb 17, 2025

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys Shares of 13,287 Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Drops By 7.1% - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

Beam Therapeutics to present updated BEAM-101 trial data - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Peregrine Investment Management Inc. Takes $3.93 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

(BEAM) Technical Data - Stock Traders Daily

Feb 15, 2025
pulisher
Feb 15, 2025

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - Benzinga

Feb 15, 2025
pulisher
Feb 14, 2025

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga India

Feb 14, 2025
pulisher
Feb 13, 2025

Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? - Yahoo Finance

Feb 13, 2025
pulisher
Feb 13, 2025

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

Sumitomo Mitsui Trust Group Inc. Acquires 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

Beam Therapeutics (BEAM) Stock Price, News & Analysis - MarketBeat

Feb 12, 2025
pulisher
Feb 11, 2025

BMO Capital maintains Outperform on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Feb 11, 2025
pulisher
Feb 11, 2025

BMO Capital maintains Outperform on Beam Therapeutics stock - MSN

Feb 11, 2025
pulisher
Feb 09, 2025

Beam Therapeutics (NASDAQ:BEAM) Trading 8% HigherShould You Buy? - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

FY2026 Earnings Estimate for BEAM Issued By HC Wainwright - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Brokers Issue Forecasts for BEAM Q1 Earnings - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat

Feb 06, 2025
pulisher
Feb 04, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

(BEAM) Long Term Investment Analysis - Stock Traders Daily

Feb 04, 2025
pulisher
Feb 04, 2025

FY2024 EPS Forecast for Beam Therapeutics Boosted by Analyst - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com Canada

Feb 03, 2025
pulisher
Feb 02, 2025

Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpWhat's Next? - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Feb 01, 2025
pulisher
Jan 31, 2025

(BEAM)Analyzing Beam Therapeutics's Short Interest - Benzinga

Jan 31, 2025
pulisher
Jan 31, 2025

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares - Simply Wall St

Jan 31, 2025
pulisher
Jan 31, 2025

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance

Jan 31, 2025

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$32.85
price up icon 1.51%
$81.36
price up icon 2.58%
$21.08
price down icon 1.36%
$372.83
price up icon 0.61%
biotechnology ONC
$238.11
price up icon 3.14%
$122.75
price up icon 2.44%
Cap:     |  Volume (24h):